Overview of the therapeutic strategies for ER positive breast cancer.
Loading...
Issue Date
2023-06
Authors
Blakely, Brianna*
Shin, Seobum*
Jin, Kideok
Degree
Advisor
Committee Members
Journal Title
Journal ISSN
Volume Title
Abstract
Estrogen Receptor is the driving transcription factor in about 75% of all breast cancers, which is the target of endocrine therapies, but drug resistance is a common clinical problem. ESR1 point mutations at the ligand binding domain are frequently identified in metastatic tumor and ctDNA (Circulating tumor DNA) derived from ER positive breast cancer patients with endocrine therapies. Although endocrine therapy and CDK4/6 inhibitor therapy have demonstrated preclinical and clinical benefits for breast cancer, the development of resistance remains a significant challenge and the detailed mechanisms, and potential therapeutic targets in advanced breast cancer yet to be revealed. Since a crosstalk between tumor and tumor microenvironment (TME) plays an important role to grow tumor and metastasis, this effect could serve as key regulators in the resistance of endocrine therapy and the transition of breast cancer cells to metastasis. In this article, we have reviewed recent progress in endocrine therapy and the contribution of TME to ER positive breast cancer.
Citation
Blakely B, Shin S, Jin K. Overview of the therapeutic strategies for ER positive breast cancer. Biochem Pharmacol. 2023 Jun;212:115552. doi: 10.1016/j.bcp.2023.115552. Epub 2023 Apr 15. PMID: 37068524; PMCID: PMC10394654.
ACPHS Research Commons URI
Description
Click on the Resource Link to access the article (may not be free).
Grants
R15 CA271221/CA/NCI NIH HHS/United States